Jpmorgan Chase & CO Rigel Pharmaceuticals Inc Transaction History

Jpmorgan Chase & CO

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Dec 26, 2024	BUY	$1.12 - $1.57 $115,038 - $161,259	102,713 New	102,713 $152,000
Q1 2024 May 10, 2024	SELL	$1.12 - $1.57 $28,566 - $40,044	-25,506 Reduced 19.89%	102,713 $152,000
Q4 2023 Dec 26, 2024	BUY	$0.72 - $1.56 $92,317 - $200,021	128,219 New	128,219 $185,000
Q4 2023 Feb 12, 2024	SELL	$0.72 - $1.56 $61,800 - $133,901	-85,834 Reduced 40.1%	128,219 $185,000
Q3 2023 Nov 14, 2023	SELL	$1.07 - $1.39 $60,979 - $79,216	-56,990 Reduced 21.03%	214,053 $231,000
Q2 2023 Aug 11, 2023	SELL	$1.12 - $1.82 $281,639 - $457,664	-251,464 Reduced 48.13%	271,043 $349,000
Q1 2023 May 18, 2023	BUY	$1.25 - $2.0 $165,248 - $264,398	132,199 Added 33.87%	522,507 $689,000
Q1 2023 May 11, 2023	BUY	$1.25 - $2.0 $273,250 - $437,200	218,600 Added 127.31%	390,308 $515,000
Q4 2022 Feb 13, 2023	BUY	$0.67 - $11.9 $28,604 - $508,046	42,693 Added 33.09%	171,708 $258,000
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $37,934 - $420,729	34,486 Added 36.48%	129,015 $152,000
Q2 2022 Aug 11, 2022	SELL	$0.67 - $3.19 $365 - $1,738	-545 Reduced 0.57%	94,529 $107,000
Q1 2022 May 11, 2022	BUY	$2.22 - $3.45 $43,014 - $66,847	19,376 Added 25.6%	95,074 $284,000
Q4 2021 Feb 10, 2022	SELL	$2.36 - $3.57 $1,239 - $1,874	-525 Reduced 0.69%	75,698 $201,000
Q3 2021 Nov 12, 2021	BUY	$3.5 - $4.5 $266,780 - $343,003	76,223 New	76,223 $276,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.81B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.